not used title
not used title
Today, in honor of National Immunization Awareness Month, we’ll take a look at how Medicare Part D supports access to critical vaccines and strengthens public health. Vaccines represent some of the most impactful advances in public health, helping to prevent the spread of many infectious diseases. Here in the United States, there are currently 16 diseases that are now preventable as a result of childhood vaccines.
A recent report found that there are nearly 260 vaccines in development by America’s biopharmaceutical companies, including dozens for COVID-19 in the pipeline. Biopharmaceutical companies are exploring a wide range of approaches to COVID-19 for older adults including increasing the doses or adding a booster to the shot. Yet no matter the approach, biopharmaceutical researchers must comply with a number of regulations throughout the development process to help ensure vaccine safety.
Continued progress in the research and development of new vaccines is important news for Americans of all ages, but especially for seniors. It is important for adults and seniors to receive certain vaccinations as they age to avoid a variety of serious conditions. The immune system naturally weakens over a patient’s lifespan and vaccines can be critical to prevent illness among the elderly, who may be particularly vulnerable to infection. For example, shingles is caused by the same virus that causes chickenpox (varicella-zoster) and can occur in adults who had chickenpox as children. It is thought that lowered immunity to infections as people grow older may be the cause.
Ensuring greater uptake of and access to vaccines will improve public health and reduce broader health care costs over time. Increasing awareness of the availability and value of vaccines, particularly among adults, can help improve vaccine rates. It is also important to provide robust insurance coverage for preventative care more broadly, including vaccines, in order to avoid vaccine-preventable diseases.
Low adult immunization rates are due to multiple barriers, including lack of information about recommended vaccines, financial hurdles, as well as technological and logistical obstacles.
For medically necessary, commercially available adult vaccines not covered under Medicare Part B, Part D covers available vaccines and, since 2012, the Centers for Medicare & Medicaid Services (CMS) has encouraged Part D plans to offer either $0 or low-cost sharing for vaccines to help increase adult immunization rates. Despite this encouragement, Part D plans continue to apply cost-sharing for vaccines that may limit access for beneficiaries. This effort to ensure vaccines are affordable and accessible to seniors is critical as illnesses attributed to vaccine-preventable diseases remains higher in adults than children.
While the biopharmaceutical works to ensure a safe and effective vaccine for COVID-19 is successful, patients of all ages, including older adults should consult with their health care provider about the appropriate vaccines to prevent against infectious diseases, including the annual influenza vaccine.
Learn more about the importance of vaccinations here. Learn more about how Medicare protects public health and improves access to needed vaccines and treatments, by following along with our new Catalyst series on Medicare Part D.
Tom Wilbur
Tom Wilbur is Deputy Vice President of Public Affairs at PhRMA where he leads the state public affairs team and Voters for Cures, PhRMA’s grassroots advocacy initiative. Prior to joining PhRMA in 2019, Tom served as a senior aide on Capitol Hill for U.S. Rep. Fred Upton and the House Energy and Commerce Committee. Tom holds an M.A. in strategic communications from Michigan State University and a B.A. in social science and history from Central Michigan University. He enjoys spending time with family and friends, volunteering, reading and golfing.
Author Twitter
Author LinkedIn
What AARP isn’t telling seniors about MFN
August 24, 2026
CMS proposal could discourage patient-centered innovation
August 18, 2026
Nearly 1 in 4 patients initially denied access to IRA medicines
August 6, 2026
Why smart vaccine policy matters
August 3, 2026
Medicare Part D at 20: Building on a strong foundation
July 23, 2026
New study: HPV vaccination helps prevent cervical cancer deaths
July 21, 2026
New research reinforces the importance of hepatitis B vaccination at birth
May 21, 2026
MFN won’t lower costs when insurers call the shots
May 8, 2026
Guest Blog: How MFN price controls could decide my health care
April 30, 2026
World Immunization Week: Putting preventable diseases in the past
April 24, 2026
States should avoid repeating the IRA’s price‑setting mistakes
April 21, 2026
ICYMI: Measles resurgence could cost U.S. nearly $8 billion over five years
April 15, 2026
Insurers routinely block seniors’ access to medicines in Medicare Part D
March 18, 2026
MFN undermines U.S. biopharmaceutical innovation
February 25, 2026
CMS puts patients and innovation at risk with MFN
February 24, 2026
Why shifting childhood vaccines to “shared clinical decision-making” puts kids at risk
February 23, 2026
New list of selected drugs highlights growing consequences of government price setting
January 28, 2026
Changes to America’s childhood vaccine schedule fail to protect our nation's kids
January 13, 2026
Guest blog: Making the most of the Medicare Prescription Payment Plan
December 8, 2025
The IRA’s price setting doesn’t guarantee lower costs or better access
November 17, 2025
New study: Measles setbacks harm health and America’s economy
October 28, 2025
Why the hepatitis B vaccine matters
October 21, 2025
What seniors can expect this open enrollment
October 14, 2025
Part D premiums are going up, while choices are going down
October 8, 2025
Vaccines and autism: Decades of scientific evidence find no link
September 22, 2025
Delivering breakthroughs and lower costs for patients
September 8, 2025
Why the vaccine injury program matters
August 18, 2025
Recognizing the importance of vaccination for American health and security
August 4, 2025
Celebrating 60 Years of Medicare
July 30, 2025
Medicare patients face higher drug costs, despite IRA promises
July 22, 2025
Answering common questions on mRNA technology
July 17, 2025
What to know about vaccine ingredients: Aluminum and thimerosal
June 24, 2025
Medicare Part D plans initially denied medicines for more than 70% of patients in four chronic disease areas
June 16, 2025
PBMs launch new ad campaign to block reforms
May 5, 2025
World Immunization Week: Highlighting the importance of vaccines for public health
April 28, 2025
What you need to know: Measles and the MMR vaccine
March 10, 2025
Improved treatments continue to lead to declining cancer mortality rates in the U.S.
February 25, 2025
CMS, don’t fall behind the rest of the medical community on obesity
February 14, 2025
Preventing and fighting disease: A look at the biopharmaceutical progress made for patients in 2024
February 3, 2025
Patients are losing as government price setting continues
January 17, 2025
A new administration poses new opportunities for patient access
December 17, 2024
Recognizing the value of disease prevention with Dr. Len Friedland from GSK
December 12, 2024
CMS needs to do better
November 4, 2024
Leveraging the power of vaccines to prevent antimicrobial resistance
October 31, 2024
From the emergency department to the CDC Advisory Committee: Key takeaways from ACIP’s recent meeting
October 30, 2024
The Patient Perspective: Vaccines
October 23, 2024
Is CMS paying attention to the growing access barriers for Medicare patients under the IRA?
October 18, 2024
Did the administration consider the importance of blood cancer medicines to patients in price setting process?
October 8, 2024
Did the administration consider the importance of blood clot medicines to patients in the price setting process?
September 25, 2024
The Inflation Reduction Act could increase costs and reduce access for millions of seniors
September 17, 2024
Are the IRA’s Part B inflation rebates lowering costs for Medicare patients? No.
September 16, 2024
Did the administration consider the value of innovative diabetes medicines in price setting process?
August 28, 2024
How to protect your children’s health this school year
August 22, 2024
New survey: Insurers confirm IRA will reduce patient treatment options
August 20, 2024
The unintended consequences of government price setting in Medicare Part D
August 16, 2024
Don’t put the government between patients and their medicines
August 7, 2024
What is the low-income subsidy program and how is it changing?
July 31, 2024
Case study: How seniors could face access disruptions because of the IRA’s price setting provisions
July 22, 2024
New Report: Vaccines continue to drive improved health outcomes
July 16, 2024
PhRMA reiterates concerns with IRA price setting program, urges CMS to mitigate harm
July 3, 2024
Showcasing the promise of biopharma at ASCO 2024
June 28, 2024
The IRA could lead to higher out-of-pocket costs for 3.5 million Medicare patients in 2026
June 25, 2024
IRA is already negatively impacting access to medicines in Part D
April 25, 2024
New study finds insurers and PBMs increasing access restrictions in Medicare Part D
April 16, 2024
World Vaccine Congress: Building on vaccine success
April 1, 2024
As the administration continues to falsely claim Medicare “negotiation,” keep these points in mind
February 1, 2024
WHO Pandemic Agreement offers opportunities and risks for American innovators
November 20, 2023
New Report: 1,600 cancer treatments and vaccines in clinical development
November 9, 2023
ICYMI: 3 takeaways on the IRA’s unintended consequences from America’s Physician Groups’ 2023 annual fall conference
November 6, 2023
What you should know about protecting your health this fall
October 16, 2023
ICYMI: Government watchdog report finds patients in Medicare Part D paid billions more for medicines than insurers and PBMs
September 28, 2023
IRA threatens seniors’ access to robust treatment options
September 26, 2023
Medicare Prescription Payment Plan will benefit patients if implemented correctly
September 21, 2023
Correcting the record: IRA’s government price setting provisions are unconstitutional
September 8, 2023
IRA changes to Part D risk access to medicines
August 24, 2023
With the first list of medicines out, let’s not forget why government price setting is bad policy
August 22, 2023
One year later IRAs unintended consequences are becoming reality
August 16, 2023
AARP’s latest misleading report
August 11, 2023
A conversation with Dr. Mike Ybarra on the current state of COVID-19
June 27, 2023
Four things for CMS to keep in mind as they implement changes to Part D
June 7, 2023
CMS guidance on IRA price setting process doubles down on bad policy
April 14, 2023
A guide to MedPAC’s Part B vote today
April 13, 2023
What they are saying: Experts reinforce that TRIPS waiver expansion is harmful and unnecessary
April 13, 2023
MedPAC proposal threatens access to medicines in Part B
April 6, 2023
CMS coverage policy is detrimental to Alzheimer’s patients
April 4, 2023
How Part B’s ASP system helps control costs for the government and seniors
March 30, 2023
PhRMA provides comments and testimony to USITC investigation on COVID-19 medicines and the TRIPS Agreement
March 30, 2023
Medicare Part B spending in four points
March 28, 2023
Celebrating the success of the COVID-19 vaccines, and looking to the future
March 27, 2023
What we’ve learned from three years of fighting COVID-19
March 20, 2023
Word of the Month: What is TRIPS?
November 29, 2022
Medicare Part D open enrollment and what recent changes mean for beneficiaries
November 17, 2022
What you should know about RSV
November 15, 2022
Word of the Month: Long COVID
October 19, 2022
Many seniors are paying more for Part D medicines than their insurer
October 18, 2022
Protecting against influenza: A conversation with David Ross, Vice President, Commercial Operations, North America, CSL Seqirus
October 13, 2022
Busting 3 Myths About Copay Coupons
October 5, 2022
A key fact the White House is reluctant to admit
September 27, 2022
A key fact the White House is reluctant to admit
September 27, 2022
Partnerships are driving global COVID-19 treatment access
September 22, 2022
CMS coverage policies restrict patient access to important treatment options for Alzheimer’s disease
September 1, 2022
Myth vs. Fact: The Senate’s latest price setting proposal
August 5, 2022
The Senate’s latest price setting proposal will undermine U.S. economic growth
August 3, 2022
Celebrating Medicare’s 57th anniversary
August 2, 2022
The Senate’s latest price setting proposal will undermine: Our health care system
July 28, 2022
The Senate’s latest price setting proposal will undermine: Patient access to medicines
July 26, 2022
New research shows competition driven by biosimilars helps control costs in Part B
July 19, 2022
ICYMI: PhRMA’s Ubl pens op-ed on IP waiver for COVID-19 technologies
July 15, 2022
Polling continues to show voters reject so-called Medicare “negotiation” once they learn about consequences for patients
July 12, 2022
CMS coverage decision restricts access to treatments for Alzheimer’s disease
June 22, 2022
Annual projections from NHE compared to actual health care spending
May 5, 2022
Three charts show how the Medicare Part D program could be improved to work better for seniors and people with disabilities
April 27, 2022
Part D 101: Three charts show how the program provides comprehensive prescription drug coverage
April 26, 2022
New Data: COVID-19 vaccine global production capacity projected to exceed 20 billion doses this year
February 24, 2022
Government price setting leaves behind families counting on new medicines
February 23, 2022
What you need to know about newly authorized COVID-19 antiviral treatments
February 22, 2022
Part B 101: Three charts show the program helps control costs for health care system and enrollees
February 18, 2022
Guest Blog: COVID-19 vaccines are the key to keeping kids healthy
February 16, 2022
PhRMA submits comments urging CMS to withdraw coverage proposal
February 11, 2022
Government price setting won’t stop insurers from shifting costs to patients
February 2, 2022
Research and development continues long after a medicine is initially approved
February 1, 2022
It’s a new year, but sadly Congress is still pursuing flawed price setting policies
January 25, 2022
Post-approval research save lives. Why is Congress trying disincentivize it?
December 17, 2021
A price control by any other name would still put patients at risk and threaten innovation
December 9, 2021
Making medicines more affordable: Making insurance work like insurance
December 8, 2021
3 things to know about the importance of post-approval research and development
December 6, 2021
New data show insurers and PBMs increase barriers to care
December 2, 2021
Global COVID-19 vaccination matters now and for the future
November 29, 2021
Guest post: Congress should not put future innovation at risk
November 29, 2021
What is missing in the current drug pricing plan
November 23, 2021
ICYMI: PhRMA CEO speaks at STAT Summit about government price setting
November 19, 2021
Three things to know about so-called Medicare negotiation polling
November 18, 2021
In the current health care debate, Congress has lost sight of what matters to U.S. voters
November 15, 2021
Making medicines more affordable: Modernizing Medicare
November 11, 2021
Understanding breakthrough COVID-19 infections
November 11, 2021
What they are saying: Government price setting for medicines is not the answer
November 4, 2021
CMS finds medication adherence saved Medicare up to 46.6B in avoided health care costs between 2013 and 2018
October 19, 2021
ICYMI: New study confirms policies like H.R. 3 could significantly reduce drug development
October 18, 2021
New poll shows Americans reject Medicare negotiation once they learn more about the policy
October 15, 2021
What is Kaiser Family Foundation up to?
October 12, 2021
The important role of antivirals in the fight against COVID-19
October 6, 2021
Industry leaders discuss the impact of the drug pricing debate
September 23, 2021
Five reasons tying VA prices to Medicare Part D misses the mark
September 22, 2021
America’s biopharmaceutical companies to Congress: Government “negotiation” is the wrong approach
September 15, 2021
A year and a half later: The biopharmaceutical industry remains committed to beating COVID-19
September 8, 2021
Recognizing National Immunization Awareness Month
August 31, 2021
Recent polling misrepresents public support for Medicare “negotiation”
August 31, 2021
Driving further innovation is critical to global vaccine equity
August 24, 2021
What they’re saying: Patient advocates want to protect Medicare from government interference
August 24, 2021
Myth vs. fact: Polling and Medicare “negotiation”
August 12, 2021
Supporting country readiness to boost global vaccine access
August 12, 2021
Ensuring global vaccine equity requires eliminating trade and regulatory barriers
August 5, 2021
ICYMI: Event spotlights how we can make Medicare work better for patients
August 4, 2021
Setting the record straight: Addressing common misconceptions about the COVID-19 vaccine
August 4, 2021
The future of the rebate rule: Will policymakers stand with patients?
August 2, 2021
Celebrating Medicare’s 56th anniversary
July 30, 2021
Increasing global access to vaccines by optimizing production
July 29, 2021
Government “negotiation” could have devastating consequences for Medicare enrollees
July 23, 2021
Guest post: Retired medics return to the field to take on vaccine delivery and disaster relief
July 23, 2021
Guest Post: A patient’s story of the long-term health impacts of COVID-19
July 21, 2021
Protecting Medicare from government interference
July 21, 2021
Dose sharing as a part of the COVID-19 global vaccine equity strategy
July 20, 2021
Promoting global vaccine equity while protecting innovation
July 15, 2021
Data shows voters strongly support protecting access to their medicines
July 15, 2021
Data shows COVID-19 vaccines are creating a pathway to a strong U.S. recovery
July 2, 2021
Medicare “negotiation” proposals threaten Americans’ access to medicines
June 30, 2021
Americans 12 years of age and older are eligible for COVID-19 vaccines
June 17, 2021
Out-of-pocket trends in Medicare Part D show rising costs for seniors
May 24, 2021
ICYMI: PhRMA president and CEO Stephen J. Ubl joins other industry leaders for a conversation on COVID-19 vaccines with Axios
May 21, 2021
Supporting India during the devastating coronavirus surge
May 20, 2021
The ABCs (and Ds) of Medicare
May 13, 2021
PhRMA CAREs Grant request for proposals: Addressing inequities in access to COVID-19 testing, therapeutics and vaccines
May 6, 2021
Ron Busby, Sr., President and CEO of the U.S. Black Chambers, Inc. on improving vaccine confidence in community
May 5, 2021
Patient safety is at the heart of COVID-19 vaccine R&D
April 26, 2021
Data shows that Americans are relying on vaccines to get us through the pandemic
April 22, 2021
Diversifying clinical trials and fighting disease requires equity and trust
April 12, 2021
Building confidence in the COVID-19 vaccine through education
March 22, 2021
ICYMI: Bipartisan lawmakers urge new administration to oppose changes to six protected classes policy
March 11, 2021
ICYMI: WSJ showcases breakthrough science of COVID-19 vaccines and implications for future medicines
March 8, 2021
Intellectual property is the key to vaccine development, manufacturing and technology sharing
March 5, 2021
Coming together to fight COVID-19: A conversation with Paul Perreault, CEO and Managing Director of CSL
February 24, 2021
Fighting variants of COVID-19
February 22, 2021
Key excerpts: PhRMA submits comments to keep the six protected classes protected
February 19, 2021
Action needed to preserve the six protected classes
February 3, 2021
Growing trend: Increased vaccine confidence
January 28, 2021
Key facts: The final rebate rule will be a positive change for patients
January 19, 2021
End of year Part D reading List
December 18, 2020
New analysis finds stark difference in coverage of breast cancer medicines for seniors in the United States and England
December 10, 2020
Guest post: How COVID-19 underscores the importance of public confidence in vaccines
December 7, 2020
No matter how you look at it, the Most Favored Nation rule is bad policy
December 1, 2020
Final rebate rule represents right way to change Medicare
December 1, 2020
Understanding the emergency use authorization process for COVID-19 vaccines
November 12, 2020
Open Enrollment: How to find a Medicare plan that meets your needs
October 14, 2020
Flu Season 2020: Why it’s time to talk to your doctor today about getting a flu shot
October 8, 2020
Three reasons why repealing the Part D non-interference clause is a bad idea
October 1, 2020
Coming together to fight COVID-19: A conversation with Albert Bourla, Chairman & CEO of Pfizer, Inc.
September 17, 2020
National Medicare Education Week: The history of Medicare Part D
September 15, 2020